Targovax is a clinical stage immuno-oncology company developing immune activators for combination therapy in cancer. Targovax has a diversified immune activator portfolio and aims to become a leader in this area. The Company’s lead product, ONCOS-102, is an oncolytic adenovirus armed with an immune-stimulating transgene, which is currently being investigated in four ongoing clinical trials.
IR Contact
News
-
April 9, 2019Targovax ASA: Annual Report 2018
-
April 9, 2019Notice of Annual General Meeting
-
March 25, 2019Targovax to hold a webcast with Q&A session
-
March 19, 2019Targovax is invited to present at Neoantigen Summit Europe, DNB SME Conference and BIO-Europe Spring